Cargando…

Clinical Investigation of the Role of Interleukin-4 and Interleukin-13 in the Evolution of Prostate Cancer

Prostate cancer is the most common cancer in men, both in the USA and Europe. Although incurable, metastatic disease can often be controlled for years with anti-androgen therapy. Once the disease becomes castrate resistant, the median survival is 18 months. There is growing evidence that the immune...

Descripción completa

Detalles Bibliográficos
Autores principales: Goldstein, Robert, Hanley, Charles, Morris, Jonathan, Cahill, Declan, Chandra, Ashish, Harper, Peter, Chowdhury, Simon, Maher, John, Burbridge, Sophie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Molecular Diversity Preservation International (MDPI) 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3763424/
https://www.ncbi.nlm.nih.gov/pubmed/24213139
http://dx.doi.org/10.3390/cancers3044281
_version_ 1782283013744230400
author Goldstein, Robert
Hanley, Charles
Morris, Jonathan
Cahill, Declan
Chandra, Ashish
Harper, Peter
Chowdhury, Simon
Maher, John
Burbridge, Sophie
author_facet Goldstein, Robert
Hanley, Charles
Morris, Jonathan
Cahill, Declan
Chandra, Ashish
Harper, Peter
Chowdhury, Simon
Maher, John
Burbridge, Sophie
author_sort Goldstein, Robert
collection PubMed
description Prostate cancer is the most common cancer in men, both in the USA and Europe. Although incurable, metastatic disease can often be controlled for years with anti-androgen therapy. Once the disease becomes castrate resistant, the median survival is 18 months. There is growing evidence that the immune system, and in particular cytokines, play an important role in prostate cancer immunosurveillance and progression. Here, we have undertaken a clinical investigation of the role of two closely related cytokines, IL-4 and IL-13 in prostate cancer. In the largest series studied to date, we show that serum IL-4, but not IL-13 is significantly elevated in castrate resistant, compared to androgen sensitive disease. Notably however, serum IL-4 levels are also raised in patients with benign prostatic disease. Analysis of benign and malignant prostate tissue demonstrates that the source of IL-4 is epithelial cells rather than infiltrating leukocytes. Together, our data are consistent with a dual role for IL-4 in prostate cancer development. In benign disease, our data add to the evidence that IL-4 serves a protective role. By contrast, the data support a direct role for IL-4 in the progression of prostate cancer from androgen responsive, to advanced castrate-resistant disease.
format Online
Article
Text
id pubmed-3763424
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Molecular Diversity Preservation International (MDPI)
record_format MEDLINE/PubMed
spelling pubmed-37634242013-09-05 Clinical Investigation of the Role of Interleukin-4 and Interleukin-13 in the Evolution of Prostate Cancer Goldstein, Robert Hanley, Charles Morris, Jonathan Cahill, Declan Chandra, Ashish Harper, Peter Chowdhury, Simon Maher, John Burbridge, Sophie Cancers (Basel) Article Prostate cancer is the most common cancer in men, both in the USA and Europe. Although incurable, metastatic disease can often be controlled for years with anti-androgen therapy. Once the disease becomes castrate resistant, the median survival is 18 months. There is growing evidence that the immune system, and in particular cytokines, play an important role in prostate cancer immunosurveillance and progression. Here, we have undertaken a clinical investigation of the role of two closely related cytokines, IL-4 and IL-13 in prostate cancer. In the largest series studied to date, we show that serum IL-4, but not IL-13 is significantly elevated in castrate resistant, compared to androgen sensitive disease. Notably however, serum IL-4 levels are also raised in patients with benign prostatic disease. Analysis of benign and malignant prostate tissue demonstrates that the source of IL-4 is epithelial cells rather than infiltrating leukocytes. Together, our data are consistent with a dual role for IL-4 in prostate cancer development. In benign disease, our data add to the evidence that IL-4 serves a protective role. By contrast, the data support a direct role for IL-4 in the progression of prostate cancer from androgen responsive, to advanced castrate-resistant disease. Molecular Diversity Preservation International (MDPI) 2011-12-16 /pmc/articles/PMC3763424/ /pubmed/24213139 http://dx.doi.org/10.3390/cancers3044281 Text en © 2011 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/)
spellingShingle Article
Goldstein, Robert
Hanley, Charles
Morris, Jonathan
Cahill, Declan
Chandra, Ashish
Harper, Peter
Chowdhury, Simon
Maher, John
Burbridge, Sophie
Clinical Investigation of the Role of Interleukin-4 and Interleukin-13 in the Evolution of Prostate Cancer
title Clinical Investigation of the Role of Interleukin-4 and Interleukin-13 in the Evolution of Prostate Cancer
title_full Clinical Investigation of the Role of Interleukin-4 and Interleukin-13 in the Evolution of Prostate Cancer
title_fullStr Clinical Investigation of the Role of Interleukin-4 and Interleukin-13 in the Evolution of Prostate Cancer
title_full_unstemmed Clinical Investigation of the Role of Interleukin-4 and Interleukin-13 in the Evolution of Prostate Cancer
title_short Clinical Investigation of the Role of Interleukin-4 and Interleukin-13 in the Evolution of Prostate Cancer
title_sort clinical investigation of the role of interleukin-4 and interleukin-13 in the evolution of prostate cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3763424/
https://www.ncbi.nlm.nih.gov/pubmed/24213139
http://dx.doi.org/10.3390/cancers3044281
work_keys_str_mv AT goldsteinrobert clinicalinvestigationoftheroleofinterleukin4andinterleukin13intheevolutionofprostatecancer
AT hanleycharles clinicalinvestigationoftheroleofinterleukin4andinterleukin13intheevolutionofprostatecancer
AT morrisjonathan clinicalinvestigationoftheroleofinterleukin4andinterleukin13intheevolutionofprostatecancer
AT cahilldeclan clinicalinvestigationoftheroleofinterleukin4andinterleukin13intheevolutionofprostatecancer
AT chandraashish clinicalinvestigationoftheroleofinterleukin4andinterleukin13intheevolutionofprostatecancer
AT harperpeter clinicalinvestigationoftheroleofinterleukin4andinterleukin13intheevolutionofprostatecancer
AT chowdhurysimon clinicalinvestigationoftheroleofinterleukin4andinterleukin13intheevolutionofprostatecancer
AT maherjohn clinicalinvestigationoftheroleofinterleukin4andinterleukin13intheevolutionofprostatecancer
AT burbridgesophie clinicalinvestigationoftheroleofinterleukin4andinterleukin13intheevolutionofprostatecancer